Targeted overexpression of α-synuclein by rAAV2/1 vectors induces progressive nigrostriatal degeneration and increases vulnerability to MPTP in mouse

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Song, Lian Kun ^a   Ma, Kai Li ^a,c   Yuan, Yu He ^a   Mu, Zheng ^a   Song, Xiu Yun ^a   Niu, Fei ^a   Han, Ning ^a   Chen, Nai Hong ^a,b  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^c INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL LOSS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENOTYPE ENVIRONMENT INTERACTION; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SENSITIVITY ANALYSIS; STRIATONIGRAL DEGENERATION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN; INTOXICATION; METABOLISM; PARKINSON DISEASE; PATHOLOGY; SUBSTANTIA NIGRA;

MUS;

ALPHA-SYNUCLEIN; ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GENETIC VECTORS; HUMANS; MALE; MICE; MPTP POISONING; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA;

EID: 84938498826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131281     Document Type: Article

References (66)

1. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997; 388(6645): 839-40. PMID: 9278044
2. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321): 2045-7. PMID: 9197268
3. Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. α-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646): 841-841. PMID: 14593171
4. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature genetics. 2009; 41(12): 1308-12. doi: 10.1038/ng.487 PMID: 19915575
5. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009; 124(6): 593-605. doi: 10.1007/s00439-008-0582-9 PMID: 18985386
6. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, et al. Parkinson-like neurodegeneration induced by targeted overexpression of synuclein in the nigrostriatal system. journal of neuroscience. 2002; 22(7): 2780-91. PMID: 11923443
7. Lee M, Hyun DH, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant α-synuclein on cell susceptibility to insult. Journal of neurochemistry. 2001; 76(4): 998-1009. PMID: 11181819
8. El-Agnaf O, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, et al. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS letters. 1998; 440(1): 71-5. PMID: 9862428
9. Wakamatsu M, Ishii A, Iwata S, Sakagami J, Ukai Y, Ono M, et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobiology of aging. 2008; 29(4): 574-85. PMID: 17174013
10. Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis. 2001; 8(3): 535-9. PMID: 11442360
11. Fernagut P-O, Chesselet M-F. Alpha-synuclein and transgenic mouse models. Neurobiol Dis. 2004; 17 (2): 123-30. doi: 10.1016/j.nbd.2004.07.001 PMID: 15474350
12. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences. 2003; 100(5): 2884-9. PMID: 12601150
13. Bianco CL, Ridet J, Schneider B, Deglon N, Aebischer P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences. 2002; 99(16): 10813-8. PMID: 12122208
14. Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, et al. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One. 2013; 8(11). doi: 10.1371/journal.pone.0081426 PMID: 24312298
15. Lauwers E, Debyser Z, Dorpe J, Strooper B, Nuttin B, Baekelandt V. Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α-Synuclein. Brain pathology. 2003; 13(3): 364-72. doi: 10.1111/j.1750-3639.2003.tb00035.x PMID: 12946025
16. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem. 2004; 91(2): 451-61. PMID: 15447678
17. Oliveras-Salva M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, et al. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener. 2013; 8(44): 1750-326. doi: 10.1186/1750-1326-8-44 PMID: 24267638
18. Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One. 2011; 6(3): e17698. doi: 10.1371/journal.pone.0017698 PMID: 21408191
19. Low K, Aebischer P. Use of viral vectors to create animal models for Parkinson's disease. Neurobiol Dis. 2012; 48(2): 189-201. doi: 10.1016/j.nbd.2011.12.038 PMID: 22227451
20. Van der Perren A, Van den Haute C, Baekelandt V. Viral Vector-Based Models of Parkinson's Disease. Curr Top Behav Neurosci. 2014; 18: 18. doi: 10.1007/7854-2014-310 PMID: 24839101
21. Mulcahy P, Walsh S, Paucard A, Rea K, Dowd E. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone. Neuroscience. 2011; 181: 234-42. doi: 10.1016/j.neuroscience.2011.01.038 PMID: 21277943
22. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx. 2005; 2(3): 484-94. doi: 10.1602/neurorx.2.3.484 PMID: 16389312
23. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci. 2009; 30(9): 475-83. doi: 10.1016/j.tips.2009.06.005 PMID: 19729209
24. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord. 1998; 1: 35-8. PMID: 9613716
25. Langston JW, Ballard PA Jr. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med. 1983 Aug 4; 309(5): 310. PMID: 6602944
26. Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog Brain Res. 2010; 184: 133-57. doi: 10.1016/S0079-6123(10)84007-5 PMID: 20887873
27. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007; 2(1): 141-51. PMID: 17401348
28. Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, et al. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. Hepatology. 2005; 42 (2): 335-42. PMID: 16025519
29. Yuan Y, Jin J, Yang B, Zhang W, Hu J, Zhang Y, et al. Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway. Cell Mol Neurobiol. 2008; 28(1): 21-33. PMID: 17712623
30. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res. 2005; 163(2): 159-67. PMID: 15941598
31. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis. 2009; 34(2): 279-90. PMID: 19385059
32. Connor TJ, Kelly JP, Leonard BE. Forced swim test-induced neurochemical endocrine, and immune changes in the rat. Pharmacology, biochemistry, and behavior. 1997; 58(4): 961-7. PMID: 9408201
33. Jethva PN, Kardani JR, Roy I. Modulation of alpha-synuclein aggregation by dopamine in the presence of MPTP and its metabolite. The FEBS journal. 2011; 278(10): 1688-98. doi: 10.1111/j.1742-4658.2011.08093.x PMID: 21410644
34. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem. 2000; 74(2): 721-9. PMID: 10646524
35. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology. 2004; 25 (5): 761-9. PMID: 15288507
36. Thomas B, Mandir AS, West N, Liu Y, Andrabi SA, Stirling W, et al. Resistance to MPTP-neurotoxicity in alpha-synuclein knockout mice is complemented by human alpha-synuclein and associated with increased beta-synuclein and Akt activation. PloS one. 2011; 6(1): 0016706. doi: 10.1371/journal.pone.0016706 PMID: 21304957
37. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. Journal of Biological Chemistry. 2006; 281(40): 29739-52. PMID: 16847063
38. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 2003; 37(4): 583-95. PMID: 12597857
39. Beyer K. α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006; 112(3): 237-51. PMID: 16845533
40. Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet. 2006; 15(20): 3012-23. PMID: 16959795
41. Ma KL, Song LK, Yuan YH, Zhang Y, Han N, Gao K, et al. The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle. Neuropharmacology. 2014; 82: 132-42. doi: 10.1016/j.neuropharm.2013.07.035 PMID: 23973294
42. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001; 2(7): 492-501. PMID: 11433374
43. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of α-synuclein in Parkinson's disease: insights from animal models. Nature Reviews Neuroscience. 2003; 4(9): 727-38. PMID: 12951565
44. Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiology of disease. 2012; 45(3): 939-53. doi: 10.1016/j.nbd.2011.12.013 PMID: 22182688
45. Chesselet MF. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol. 2008; 209(1): 22-7. PMID: 17949715
46. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984; 120(2): 574-8. PMID: 6428396
47. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A. 1985; 82(7): 2173-7. PMID: 3872460
48. Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr. 2004; 36(4): 375-9. PMID: 15377875
49. Luchtman DW, Shao D, Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav. 2009; 98(1-2): 130-8. doi: 10.1016/j.physbeh.2009.04.021 PMID: 19410592
50. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 2008; 105(2): 763-8. doi: 10.1073/pnas.0711053105 PMID: 18178617
51. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2): 160-4. PMID: 11813001
52. Schell H, Hasegawa T, Neumann M, Kahle PJ. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience. 2009; 160(4): 796-804. doi: 10.1016/j.neuroscience.2009.03.002 PMID: 19272424
53. Sugeno N, Takeda A, Hasegawa T, Kobayashi M, Kikuchi A, Mori F, et al. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem. 2008; 283 (34): 23179-88. doi: 10.1074/jbc.M802223200 PMID: 18562315
54. Chau KY, Ching HL, Schapira AH, Cooper JM. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem. 2009; 110(3): 1005-13. doi: 10.1111/j.1471-4159.2009.06191.x PMID: 19493164
55. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005; 8(5): 657-63. PMID: 15834418
56. Xie W, Chung KK. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. J Neurochem. 2012; 122(2): 404-14. doi: 10.1111/j.1471-4159.2012.07769.x PMID: 22537068
57. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci. 2008; 28(30): 7687-98. doi: 10.1523/JNEUROSCI.0143-07.2008 PMID: 18650345
58. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688): 1292-5. PMID: 15333840
59. Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging. 2010; 31(6): 953-68. doi: 10.1016/j.neurobiolaging.2008.07.008 PMID: 18715677
60. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012; 338 (6109): 949-53. doi: 10.1126/science.1227157 PMID: 23161999
61. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011; 121(2): 715-25. doi: 10.1172/JCI43366 PMID: 21245577
62. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A. 2013; 110(48): 19555-60. doi: 10.1073/pnas.1318268110 PMID: 24218576
63. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106(31): 13010-5. doi: 10.1073/pnas.0903691106 PMID: 19651612
64. Dauer W, Kholodilov N, Vila M, Trillat A- C, Goodchild R, Larsen KE, et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences. 2002; 99(22): 14524-9. PMID: 12376616
65. Rathke-Hartlieb S, Kahle PJ, Neumann M, Ozmen L, Haid S, Okochi M, et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem. 2001; 77(4): 1181-4. PMID: 11359883
66. Dong Z, Ferger B, Feldon J, Bueler H. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J Neurobiol. 2002; 53(1): 1-10. PMID: 12360578